Ozempic & Mounjaro: Same Shot. Opposite Results.

Video Description

Why do some people thrive on Ozempic, Mounjaro, or other GLP1 meds while others look 10-20 years older? As a pathologist, I see the tissue and cellular truth that the scale hides. Two people can take the exact same dose of Ozempic or Mounjaro or any GLP-1 medication but get opposite biological results: Repair or Decay. In this video, I break down the Biological Cost of GLP-1 medications. I explain why some users develop "Ozempic Face" and sarcopenia (muscle rotting), while others reverse insulin resistance and regenerate. We will cover: 1. The difference between the Thrive Phenotype vs. Deterioration Phenotype. 2. The hidden danger of "Skinny Fat" on GLP-1s. 3. How to protect your muscle mass and collagen during rapid weight loss. 4. The science of Autophagy vs. Starvation. Scientific References: 1. STEP 1 (Semaglutide Weight Loss): Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. 2. SURMOUNT-1 (Tirzepatide Weight Loss): Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. 3. STEP-HFpEF (Heart Failure): Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023. 4. SELECT (Cardiovascular Outcomes): Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. 5. FLOW (Kidney Outcomes): Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. 6. SUSTAIN-6 (Retinopathy Signal): Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. 7. Gallbladder Risk: He L, et al. Association of GLP-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Intern Med. 2022. 8. GI Adverse Events: Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023. 9. Suicidality Evaluation: Wang W, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. 10. Perioperative Guidelines: Joshi GP, et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Anesthesiology. 2023. 11. Body Composition (STEP 1 Analysis): McCrimmon RJ, et al. Effects of semaglutide on body composition in adults with overweight or obesity. Diabetes Obes Metab. 2021. 12. Weight Regain (STEP 1 Extension): Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. 13. Weight Regain (SURMOUNT-4): Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024. 14. GLP-1 Physiology: Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022. 15. GLP-1 Review: Müller TD, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019. Medical Disclaimer: Call 911 or your local emergency line in case of an emergency. The content of this video is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. KEY TIMESTAMPS: 0:00 - The Paradox: Same Drug, Opposite Outcomes 2:21 - Weight Loss ≠ Metabolic Repair (Critical Concept) 4:50 - How GLP-1s Actually Work (Beyond Appetite) 14:21 - The 3-Dial Framework: Who Thrives vs Who Struggles 16:33 - Thrive Phenotype A: High Appetite Drive + Insulin Resistance 18:12 - Thrive Phenotype B: Inflammation-Driven Weight 19:02 - Thrive Phenotype C: Cardiometabolic High Risk 20:17 - Deterioration Phenotype 1: Low Reserve/Frailty Risk 21:51 - Deterioration Phenotype 2: GI Motility Issues 24:02 - Deterioration Phenotype 3: Gallbladder Risk 25:01 - Deterioration Phenotype 4: Diabetes + Eye Disease Risk 26:16 - Deterioration Phenotype 5: Trauma + Dysregulation 28:00 - Do GLP-1s Cause Suicidality? (FDA Update) 29:25 - Surgery Guidelines Update 29:46 - Pancreatitis Risk Explained 30:19 - THE THRIVE PROTOCOL (How to Succeed) 31:00 - Rule 1: Protect Lean Mass Like an Organ 31:51 - Rule 2: Make Protein Automatic 32:34 - Rule 3: Resistance Training Protocol 33:31 - Rule 4: Gut Insurance (Fiber + Hydration) 33:96 - Rule 5: Slow Titration = Precision 34:44 - Rule 6: Watch for Deterioration Signals 35:33 - Pre-Flight Checklist Before Starting 37:14 - The Off-Ramp Problem: What Happens When You Stop 39:43 - Final Synthesis + Action Steps #Ozempic #Mounjaro #WeightLoss #Pathology #MetabolicHealth #Longevity #Medicine